Fig. 1: Survival outcomes. | Blood Cancer Journal

Fig. 1: Survival outcomes.

From: Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Fig. 1

A PFS-IRC. B PFS-INV. C OS. aGiven the availability of both IRC- and INV-assessed data. CI confidence interval, CLL chronic lymphocytic leukemia, COVID-19 coronavirus disease-19, EM effect modifier, HR hazard ratio, INV investigator, IPD individual patient-level data, IRC independent review committee, MAIC matching-adjusted indirect comparison, ORR overall response rate, OS overall survival, PF prognostic factor, PFS progression-free survival, RCT randomized clinical trial, R/R relapsed refractory, SLL small lymphocytic lymphoma.

Back to article page